drugset / Trial / NCT05066022
A Study to Access the Safety and Efficacy of CT0590 in Patients With Relapsed and/or Refractory Multiple Myeloma
Unknown
24 enrolled
The First Affiliated Hospital of Soochow University
CARsgen Therapeutics Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, single arm study to evaluate the safety and tolerability of treatment with CT0590 CAR T in patients with relapsed and/or refractory multiple myeloma.
Timeline
- Start
- 2021-10-28
- Primary completion
- 2022-08-30
- Completion
- 2024-07-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CT0590 | Cell therapy | — | — |